Base de dados : MEDLINE
Pesquisa : C05.116.198.816.750 [Categoria DeCS]
Referências encontradas : 3035 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 304 ir para página                         

  1 / 3035 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28719612
[Au] Autor:Da Silva Martins J; Castro JH; Sainz Rueda NA; Dos Reis LM; Jorgetti V; Affonso Moysés RM; Caramori JT
[Ad] Endereço:Nephrology, Department of Internal Medicine, Faculdade de Medicina Botucatu Univ. Estadual Paulista-UNESP. Botucatu, Brazil.
[Ti] Título:Renal osteodystrophy in the obesity era: Is metabolic syndrome relevant?
[So] Source:PLoS One;12(7):e0180387, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Observational studies have shown a beneficial effect of obesity on bone health; however, most of those studies were not based on bone biopsies. Metabolic syndrome (MetS) could have an effect on bone remodeling. However, there are no data on the effects of MetS in the presence of renal osteodystrophy. OBJECTIVE: The aim of this study was to investigate associations between MetS and renal osteodystrophy using the bone histomorphometric turnover-mineralization-volume (TMV) classification. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: This observational cross-sectional study included 55 hemodialysis patients (28 women/27 men) who were evaluated for MetS and bone histomorphometry. Biochemical parameters included calcium, phosphorus, alkaline phosphatase, intact parathyroid hormone (iPTH), 25-hydroxyvitamin D, free serum leptin, fibroblast growth factor 23 (FGF23), intact osteocalcin, sclerostin (Scl), glucose, insulin, and thyroid hormones. Robust models of multivariate linear regressions were used for the statistical analyses. RESULTS: Females had higher iPTH levels (1,143 vs. 358, p = 0.02). Patients with normal bone volume (BV/TV) had a higher prevalence of MetS (73.6% vs. 41.7%, p = 0.02) and higher serum phosphorus, C-terminal FGF23 and insulin levels. The multivariate regression analysis showed that low-density lipoprotein cholesterol (LDL) was positively correlated with bone formation rate (BFR/BS) and negatively associated with mineralization lag time. Bone volume was negatively associated with age but positively associated with MetS. Body mass index (BMI) was not correlated with any of the bone histomorphometric parameters. CONCLUSION: Our results suggest that MetS is not a risk factor for low bone volume in hemodialysis patients. Furthermore, BMI alone was not related to bone volume in this population.
[Mh] Termos MeSH primário: Distúrbio Mineral e Ósseo na Doença Renal Crônica/complicações
Síndrome Metabólica/complicações
Obesidade/complicações
[Mh] Termos MeSH secundário: Adulto
Idoso
Densidade Óssea
Proteínas Morfogenéticas Ósseas/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/patologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/fisiopatologia
Estudos Transversais
Feminino
Fatores de Crescimento de Fibroblastos/sangue
Marcadores Genéticos
Seres Humanos
Resistência à Insulina
Leptina/sangue
Masculino
Meia-Idade
Osteocalcina/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Morphogenetic Proteins); 0 (Genetic Markers); 0 (Leptin); 0 (SOST protein, human); 0 (fibroblast growth factor 23); 104982-03-8 (Osteocalcin); 62031-54-3 (Fibroblast Growth Factors)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0180387


  2 / 3035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28704404
[Au] Autor:Yaguchi A; Tatemichi S; Takeda H; Kobayashi M
[Ad] Endereço:Pharmacology Research Laboratory, R&D., Kissei Pharmaceutical Co., Ltd., Azumino-City, Nagano-Pref., Japan.
[Ti] Título:PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.
[So] Source:PLoS One;12(7):e0180430, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The effects of PA21, a novel iron-based and non-calcium-based phosphate binder, on hyperphosphatemia and its accompanying bone abnormality in chronic kidney disease-mineral and bone disorder (CKD-MBD) were evaluated. Rats with adenine-induced chronic renal failure (CRF) were prepared by feeding them an adenine-containing diet for four weeks. They were also freely fed a diet that contained PA21 (0.5, 1.5, and 5%), sevelamer hydrochloride (0.6 and 2%) or lanthanum carbonate hydrate (0.6 and 2%) for four weeks. Blood biochemical parameters were measured and bone histomorphometry was performed for femurs, which were isolated after drug treatment. Serum phosphorus and parathyroid hormone (PTH) levels were higher in the CRF rats. Administration of phosphate binders for four weeks decreased serum phosphorus and PTH levels in a dose-dependent manner and there were significant decreases in the AUC0-28 day of these parameters in 5% PA21, 2% sevelamer hydrochloride, and 2% lanthanum carbonate hydrate groups compared with that in the CRF control group. Moreover, osteoid volume improved significantly in 5% of the PA21 group, and fibrosis volume and cortical porosity were ameliorated in 5% PA21, 2% sevelamer hydrochloride, and 2% lanthanum carbonate hydrate groups. These results suggest that PA21 is effective against hyperphosphatemia, secondary hyperparathyroidism, and bone abnormalities in CKD-MBD as sevelamer hydrochloride and lanthanum carbonate hydrate are, and that PA21 is a new potential alternative to phosphate binders.
[Mh] Termos MeSH primário: Distúrbio Mineral e Ósseo na Doença Renal Crônica/dietoterapia
Compostos Férricos/administração & dosagem
Falência Renal Crônica/induzido quimicamente
Lantânio/administração & dosagem
Sevelamer/administração & dosagem
[Mh] Termos MeSH secundário: Adenina/efeitos adversos
Animais
Distúrbio Mineral e Ósseo na Doença Renal Crônica/metabolismo
Modelos Animais de Doenças
Relação Dose-Resposta a Droga
Compostos Férricos/farmacologia
Falência Renal Crônica/complicações
Falência Renal Crônica/metabolismo
Lantânio/farmacologia
Masculino
Hormônio Paratireóideo/sangue
Fósforo/sangue
Ratos
Sevelamer/farmacologia
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ferric Compounds); 0 (PA21 compound); 0 (Parathyroid Hormone); 27YLU75U4W (Phosphorus); 490D9F069T (lanthanum carbonate); 6I3K30563S (Lanthanum); 9YCX42I8IU (Sevelamer); JAC85A2161 (Adenine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170714
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0180430


  3 / 3035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28682036
[Au] Autor:Bellasi A; Mangano M; Galassi A; Cozzolino M
[Ad] Endereço:U.O.C. di Nefrologia, Dialisi, Ospedale Sant'Anna-Como, ASST-Lariana, Como, Italy.
[Ti] Título:[CKD-MBD, cardiovascular involvement and prognosis].
[So] Source:G Ital Nefrol;34(Suppl 69):150-161, 2017 Mar.
[Is] ISSN:1724-5990
[Cp] País de publicação:Italy
[La] Idioma:ita
[Ab] Resumo:Chronic low-grade inflammation is emerging as the pathophysiological mechanism underlying of the several chronic degenerative diseases. Atherosclerosis, inflammation and oxidative stress are some of the issues that arise from the general context of chronic inflammation. In this manuscript we analyzed the role of the immune system, metabolism and inflammation's molecular mediators in order to show an overview about only apparently different problems. Finally, we proposed some possible solutions to improve the survival and quality of life of patient with chronic kidney disease.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/etiologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/complicações
[Mh] Termos MeSH secundário: Distúrbio Mineral e Ósseo na Doença Renal Crônica/tratamento farmacológico
Distúrbio Mineral e Ósseo na Doença Renal Crônica/metabolismo
Seres Humanos
Fósforo/metabolismo
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
27YLU75U4W (Phosphorus)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE


  4 / 3035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28495360
[Au] Autor:Hanudel MR; Froch L; Gales B; Jüppner H; Salusky IB
[Ad] Endereço:Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA. Electronic address: mhanudel@mednet.ucla.edu.
[Ti] Título:Fractures and Osteomalacia in a Patient Treated With Frequent Home Hemodialysis.
[So] Source:Am J Kidney Dis;70(3):445-448, 2017 Sep.
[Is] ISSN:1523-6838
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bone deformities and fractures are common consequences of renal osteodystrophy in the dialysis population. Persistent hypophosphatemia may be observed with more frequent home hemodialysis regimens, but the specific effects on the skeleton are unknown. We present a patient with end-stage renal disease treated with frequent home hemodialysis who developed severe bone pain and multiple fractures, including a hip fracture and a tibia-fibula fracture complicated by nonunion, rendering her nonambulatory and wheelchair bound for more than a year. A bone biopsy revealed severe osteomalacia, likely secondary to chronic hypophosphatemia and hypocalcemia. Treatment changes included the addition of phosphate to the dialysate, a higher dialysate calcium concentration, and increased calcitriol dose. Several months later, the patient no longer required a wheelchair and was able to ambulate without pain. Repeat bone biopsy revealed marked improvements in bone mineralization and turnover parameters. Also, with increased dialysate phosphate and calcium concentrations, as well as increased calcitriol, circulating fibroblast growth factor 23 levels increased.
[Mh] Termos MeSH primário: Fraturas Ósseas
Hemodiálise no Domicílio/efeitos adversos
Hipofosfatemia/diagnóstico
Falência Renal Crônica/terapia
Osteomalacia
Fosfatos
[Mh] Termos MeSH secundário: Calcificação Fisiológica/efeitos dos fármacos
Calcificação Fisiológica/fisiologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/diagnóstico
Distúrbio Mineral e Ósseo na Doença Renal Crônica/etiologia
Soluções para Diálise/farmacologia
Gerenciamento Clínico
Feminino
Fraturas Ósseas/diagnóstico
Fraturas Ósseas/etiologia
Fraturas Ósseas/terapia
Hemodiálise no Domicílio/métodos
Seres Humanos
Testes de Função Renal/métodos
Efeitos Adversos de Longa Duração/sangue
Efeitos Adversos de Longa Duração/diagnóstico
Meia-Idade
Osteomalacia/sangue
Osteomalacia/diagnóstico
Osteomalacia/etiologia
Fosfatos/administração & dosagem
Fosfatos/metabolismo
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dialysis Solutions); 0 (Phosphates)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170513
[St] Status:MEDLINE


  5 / 3035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28493902
[Au] Autor:Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
[Ad] Endereço:University of Antwerp, Dept. Biomedical Sciences, Laboratory of Pathophysiology, Wilrijk, Belgium.
[Ti] Título:Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
[So] Source:PLoS One;12(5):e0176411, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Mounting evidence indicates that a disturbed Wnt-ß-catenin signaling may be involved in the pathogenesis of chronic kidney disease-mineral and bone and mineral disorder (CKD-MBD). Data on the impact of CKD on circulating levels of the Wnt antagonists sclerostin and Dickkopf related protein 1 (DKK1) and the relationship with laboratory parameters of CKD-MBD are incomplete. METHODS: We analyzed serum sclerostin and DKK1 in 308 patients across the stages of chronic kidney disease (kDOQI stage 1-2 n = 41; CKD stage 3 n = 54; CKD stage 4-5 n = 54; hemodialysis n = 100; peritoneal dialysis n = 59) as well as in 49 healthy controls. We investigated associations with demographics, renal function, parameters of mineral metabolism including 25(OH) vitamin D, 1,25(OH)2 vitamin D, biointact fibroblast growth factor 23 (FGF23), and parathyroid hormone (PTH), and bone turnover markers. RESULTS: Serum sclerostin, but not DKK1, increases in more advanced stages of CKD and associates with PTH, phosphate, and 1,25(OH)2 vitamin D concentrations. Bone turnover markers are highest in hemodialysis patients presenting the combination of high PTH with low sclerostin level. Serum DKK1 levels are lower in CKD patients than in controls and are not associated with laboratory parameters of mineral metabolism. Interestingly, a direct association between DKK1 and platelet count was observed. CONCLUSION: In CKD, serum levels of the Wnt inhibitors DKK1 and sclerostin are unrelated, indicating different sites of origin and/ or different regulatory mechanisms. Sclerostin, as opposed to DKK1, may qualify as a biomarker of CKD-MBD, particularly in dialysis patients. DKK1 serum levels, remarkably, correlate almost uniquely with blood platelet counts.
[Mh] Termos MeSH primário: Proteínas Morfogenéticas Ósseas/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/sangue
Peptídeos e Proteínas de Sinalização Intercelular/sangue
Rim/metabolismo
[Mh] Termos MeSH secundário: Idoso
Plaquetas/metabolismo
Distúrbio Mineral e Ósseo na Doença Renal Crônica/fisiopatologia
Feminino
Fatores de Crescimento de Fibroblastos/sangue
Marcadores Genéticos
Voluntários Saudáveis
Seres Humanos
Rim/patologia
Masculino
Meia-Idade
Hormônio Paratireóideo/sangue
Diálise Peritoneal
Fosfatos/metabolismo
Diálise Renal
Vitamina D/sangue
Via de Sinalização Wnt/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Morphogenetic Proteins); 0 (DKK1 protein, human); 0 (Genetic Markers); 0 (Intercellular Signaling Peptides and Proteins); 0 (Parathyroid Hormone); 0 (Phosphates); 0 (SOST protein, human); 0 (fibroblast growth factor 23); 1406-16-2 (Vitamin D); 62031-54-3 (Fibroblast Growth Factors)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170512
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0176411


  6 / 3035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28299319
[Au] Autor:Sun YP; Yang WJ; Li SH; Han YY; Liu J
[Ad] Endereço:Department of Nephrology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
[Ti] Título:Clinical Epidemiology of Mineral Bone Disorder Markers in Prevalent Hemodialysis Patients in the Xinjiang Uyghur Autonomous Region in China.
[So] Source:Biomed Res Int;2017:2516934, 2017.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We investigated the clinical epidemiology of mineral bone disorder markers in prevalent hemodialysis (HD) patients in Xinjiang, the largest province in China. Data were obtained from 59 hospitals. A total of 3725 patients tracked from January 1 to December 31, 2014, were enrolled. Serum calcium (Ca) levels, phosphorus (P) levels, and intact parathyroid hormone (iPTH) levels were analyzed. Serum Ca levels were lower compared to the International Dialysis Outcomes and Practice Patterns Study (DOPPS4) and the Chinese DOPPS. The hypercalcemia rate was similar to DOPPS4 and lower than in the Chinese DOPPS. Serum P levels were higher than in DOPPS4 and lower than those in the Chinese DOPPS. Hyperphosphatemia rates were higher than DOPPS4 and lower than Chinese DOPPS. Serum iPTH levels were higher than in DOPPS4 and the Chinese DOPPS. We demonstrated higher serum P and iPTH levels in Xinjiang HD patients than in the DOPPS4 and Chinese DOPPS. In contrast, serum Ca levels were lower than the other two studies. High hypocalcemia and hyperphosphatemia rates may suggest that HD services in Xinjiang are inadequate. A multidiscipline chronic kidney disease (CKD) care program needs to be established to improve chronic kidney disease-mineral and bone disorder (CKD-MBD) target achievement in Xinjiang.
[Mh] Termos MeSH primário: Distúrbio Mineral e Ósseo na Doença Renal Crônica/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/terapia
Diálise Renal
[Mh] Termos MeSH secundário: Idoso
Calcificação Fisiológica
Cálcio/sangue
China/epidemiologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/epidemiologia
Estudos Transversais
Feminino
Seres Humanos
Hiperfosfatemia/sangue
Hipocalcemia/sangue
Masculino
Meia-Idade
Hormônio Paratireóideo/sangue
Fósforo/sangue
Prevalência
Sistema de Registros
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Parathyroid Hormone); 27YLU75U4W (Phosphorus); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE
[do] DOI:10.1155/2017/2516934


  7 / 3035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28248961
[Au] Autor:Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
[Ad] Endereço:Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
[Ti] Título:Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
[So] Source:PLoS One;12(3):e0171028, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chronic kidney disease-mineral and bone disorder (CKD-MBD), a complication of chronic kidney disease, has been linked to reduced quality and length of life. High serum phosphate levels that result from CKD-MBD require phosphate-lowering agents, also known as phosphate binders. The objective of this systematic review is to compare the effects of available phosphate binders on laboratory outcomes in patients with CKD-MBD. METHODS: Data sources included MEDLINE and EMBASE from January 1996 to April 2016, and the Cochrane Register of Controlled Trials up to April 2016. Teams of two reviewers, independently and in duplicate, screened titles and abstracts and potentially eligible full text reports to determine eligibility, and subsequently abstracted data and assessed risk of bias in eligible randomized controlled trials (RCTs). Eligible trials enrolled patients with CKD-MBD and randomized them to receive calcium-based phosphate binders (delivered as calcium acetate, calcium citrate or calcium carbonate), non-calcium-based phosphate binders (NCBPB) (sevelamer hydrochloride, sevelamer carbonate, lanthanum carbonate, sucroferric oxyhydroxide and ferric citrate), phosphorus restricted diet (diet), placebo or no treatment and reported effects on serum levels of phosphate, calcium and parathyroid hormone. We performed Bayesian network meta-analyses (NMA) to calculate the effect estimates (mean differences) and 95% credible intervals for serum levels of phosphate, calcium and parathyroid hormone. We calculated direct, indirect and network meta-analysis estimates using random-effects models. We applied the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to rate the quality of evidence for each pairwise comparison. RESULTS: Our search yielded 1108 citations; 71 RCTs were retrieved for full review and 16 proved eligible. Including an additional 13 studies from a previous review, 29 studies that enrolled 8335 participants proved eligible; 26 trials provided data for quantitative synthesis. Sevelamer, lanthanum, calcium, iron, diet and combinations of active treatments (calcium or sevelamer or lanthanum and combination of calcium and sevelamer) resulted in significantly lower serum phosphate as compared to placebo (moderate to very low quality of evidence). We found no statistically significant differences between active treatment categories in lowering serum phosphate. Sevelamer, lanthanum and diet resulted in lower serum calcium compared to calcium (moderate quality evidence for lanthanum and diet; low quality evidence for Sevelamer). Iron, sevelamer and calcium yielded lower parathyroid hormone levels as compared to lanthanum. Meta-regression analyses did not yield a statistically significant association between treatment effect and trial duration. DISCUSSION/CONCLUSIONS: We found few differences between treatments in impact on phosphate and differences in parathyroid hormone. Relative to calcium, sevelamer, lanthanum and diet showed significant reduction in serum calcium from baseline. Treatment recommendations should be based on impact on patient-important outcomes rather than on surrogate outcomes. Systematic review registration: PROSPERO CRD-42016032945.
[Mh] Termos MeSH primário: Cálcio/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/terapia
Hormônio Paratireóideo/sangue
Fosfatos/sangue
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Parathyroid Hormone); 0 (Phosphates); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170816
[Lr] Data última revisão:
170816
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0171028


  8 / 3035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28152049
[Au] Autor:Jeong S; Oh JM; Oh KH; Kim IW
[Ad] Endereço:College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
[Ti] Título:Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients.
[So] Source:PLoS One;12(2):e0170535, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mineral and bone disorder (MBD) is observed universally in patients with chronic kidney disease (CKD). Detrimental MBD-related skeletal changes include increased prevalence of fracture, cardiovascular disease, and mortality. MicroRNAs (miRNAs) have been identified as useful biomarkers in various diseases, and the aim of this study was to identify miRNAs associated with parathyroid hormone level in peritoneal dialysis (PD) patients. Fifty-two PD patients were enrolled and grouped by their intact parathyroid hormone (iPTH) level; 11 patients had low iPTH (<150 pg/mL) and 41 patients had high iPTH (≥150 pg/mL). Total RNA was extracted from whole blood samples. Total RNA from 15 patients (7 and 8 patients in the low and high iPTH groups, respectively) underwent miRNA microarray analysis, and three differentially upregulated (>2-fold change) miRNAs previously associated with human disease were selected for real-time quantitative PCR (qPCR) analysis. Interaction analyses between miRNAs and genes were performed by using TargetScan and the KEGG pathway database. Microarray results revealed 165 miRNAs were differentially expressed between patients with high iPTH levels and low iPTH levels. Of those miRNAs, 81 were upregulated and 84 were downregulated in patients with high iPTH levels. Expression levels of miR-1299, miR-3680-5p, and miR-548b-5p (previously associated with human disease) in 52 patients were analyzed by using qPCR. MiR-3680-5p was differentially expressed in low and high iPTH patients (P < 0.05). The predicted target genes of miR-3680-5p were USP6, USP32, USP46, and DLT, which are involved in the ubiquitin proteolysis pathway. This pathway has roles in PTH and parathyroid hormone related protein degradation and proteolysis. The mechanisms involved in the associations among low PTH, adynamic bone disease, miR-3680-5p, and the target genes should be explored further in order to elucidate their roles in CKD-MBD development.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/epidemiologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/epidemiologia
Fraturas Ósseas/epidemiologia
MicroRNAs/genética
Hormônio Paratireóideo/sangue
Diálise Peritoneal/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Distúrbio Mineral e Ósseo na Doença Renal Crônica/mortalidade
Distúrbio Mineral e Ósseo na Doença Renal Crônica/terapia
Endopeptidases/genética
Feminino
Marcadores Genéticos/genética
Seres Humanos
Masculino
MicroRNAs/biossíntese
Meia-Idade
Análise de Sequência com Séries de Oligonucleotídeos
Glândulas Paratireoides/metabolismo
Estudos Prospectivos
Proteínas Proto-Oncogênicas/genética
Reação em Cadeia da Polimerase em Tempo Real
República da Coreia
Ubiquitina Tiolesterase/genética
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Genetic Markers); 0 (MIRN3680 microRNA, human); 0 (MicroRNAs); 0 (Parathyroid Hormone); 0 (Proto-Oncogene Proteins); EC 3.1.2.15 (USP10 protein, human); EC 3.1.2.15 (USP6 protein, human); EC 3.4.- (Endopeptidases); EC 3.4.- (ubiquitin-specific peptidase 46, human); EC 3.4.19.12 (Ubiquitin Thiolesterase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170203
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0170535


  9 / 3035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28120569
[Au] Autor:Kwon YE; Lee MJ; Park KS; Han SH; Yoo TH; Oh KH; Lee J; Lee KB; Chung W; Kim YH; Ahn C; Choi KH
[Ad] Endereço:Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
[Ti] Título:Cystatin C is Better than Serum Creatinine for Estimating Glomerular Filtration Rate to Detect Osteopenia in Chronic Kidney Disease Patients.
[So] Source:Yonsei Med J;58(2):380-387, 2017 Mar.
[Is] ISSN:1976-2437
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Recent studies have reported that loss of bone mass is associated with renal function decline and increased fracture risks in chronic kidney disease (CKD) patients. The aim of this study was to investigate the best estimated glomerular filtration rate (eGFR) equation to detect osteopenia in CKD patients. MATERIALS AND METHODS: This was a cross-sectional study, and 780 patients aged 50 years or above were classified into normal bone mass or osteopenia groups according to the -1.0 of T-scores at total hip and femur neck. Comparisons of area under the receiver operating characteristic (ROC) curves (AUC) were performed to investigate significant differences among three eGFR formulas: Modification of Diet in Renal Disease, CKD-Epidemiology Collaboration (EPI) creatinine, and CKD-EPI cystatin C (CKD-EPI-Cys). RESULTS: The mean age was 61 years old and the proportion of females was 37.3%. The total hip osteopenia group showed lower CKD-EPI-Cys eGFR levels (osteopenia group, 33.3±19.0 mL/min/1.73 m²; normal group, 48.1±26.2 mL/min/1.73 m², p<0.001). In multiple logistic regression analysis, CKD-EPI-Cys eGFR was independently associated with osteopenia at the total hip (per 1 mL/min/1.73 m² increase, odds ratio 0.98, 95% confidence interval 0.97-0.99, p=0.004) after adjusting for confounding variables. ROC curve analyses indicated that CKD-EPI-Cys shows the largest AUC for osteopenia at the total hip (AUC=0.678, all p<0.01) and the femur neck (AUC=0.665, all p<0.05). CONCLUSION: Decreased renal function assessed by CKD-EPI-Cys equation correlates with osteopenia better than creatinine-based methods in CKD patients, and the CKD-EPI-Cys formula might be a useful tool to assess skeletal-related event risks.
[Mh] Termos MeSH primário: Doenças Ósseas Metabólicas/diagnóstico
Distúrbio Mineral e Ósseo na Doença Renal Crônica/diagnóstico
Creatinina/sangue
Cistatina C/sangue
Taxa de Filtração Glomerular
Insuficiência Renal Crônica/complicações
[Mh] Termos MeSH secundário: Adulto
Idoso
Biomarcadores/sangue
Doenças Ósseas Metabólicas/sangue
Doenças Ósseas Metabólicas/fisiopatologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/fisiopatologia
Estudos Transversais
Feminino
Seres Humanos
Masculino
Meia-Idade
Curva ROC
Insuficiência Renal Crônica/sangue
Insuficiência Renal Crônica/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Cystatin C); AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170126
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2017.58.2.380


  10 / 3035 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28083765
[Au] Autor:Fukagawa M; Inaba M; Yokoyama K; Shigematsu T; Ando R; Miyamoto KI; For Japan CKD-MBD Forum
[Ad] Endereço:Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, Kanagawa, 259-1193, Japan. fukagawa@tokai-u.jp.
[Ti] Título:An introduction to CKD-MBD research: restart for the future.
[So] Source:Clin Exp Nephrol;21(Suppl 1):1-3, 2017 Mar.
[Is] ISSN:1437-7799
[Cp] País de publicação:Japan
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças Ósseas Metabólicas/etiologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/etiologia
Minerais/metabolismo
Insuficiência Renal Crônica/complicações
Pesquisa
[Mh] Termos MeSH secundário: Doenças Ósseas Metabólicas/tratamento farmacológico
Doenças Ósseas Metabólicas/metabolismo
Distúrbio Mineral e Ósseo na Doença Renal Crônica/tratamento farmacológico
Distúrbio Mineral e Ósseo na Doença Renal Crônica/metabolismo
Previsões
Seres Humanos
Insuficiência Renal Crônica/tratamento farmacológico
Insuficiência Renal Crônica/metabolismo
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (Minerals)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170114
[St] Status:MEDLINE
[do] DOI:10.1007/s10157-016-1372-7



página 1 de 304 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde